E
Elizabeth C Smyth
Researcher at Cambridge University Hospitals NHS Foundation Trust
Publications - 173
Citations - 6437
Elizabeth C Smyth is an academic researcher from Cambridge University Hospitals NHS Foundation Trust. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 28, co-authored 142 publications receiving 3613 citations. Previous affiliations of Elizabeth C Smyth include Mater Misericordiae University Hospital & European Organisation for Research and Treatment of Cancer.
Papers
More filters
Journal ArticleDOI
Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Georgios Vlachogiannis,Somaieh Hedayat,Alexandra Vatsiou,Yann Jamin,Javier Fernández-Mateos,Khurum Khan,Khurum Khan,Andrea Lampis,Katherine Eason,Ian Said Huntingford,Rosemary Burke,Mihaela Rata,Dow-Mu Koh,Dow-Mu Koh,Nina Tunariu,Nina Tunariu,David J. Collins,Sanna Hulkki-Wilson,Chanthirika Ragulan,Inmaculada Spiteri,Sing Yu Moorcraft,Ian Chau,Sheela Rao,David Watkins,Nicos Fotiadis,Maria Antonietta Bali,Maria Antonietta Bali,Mahnaz Darvish-Damavandi,Hazel Lote,Hazel Lote,Zakaria Eltahir,Elizabeth C Smyth,Ruwaida Begum,Paul A. Clarke,Jens C. Hahne,Mitchell Dowsett,Johann S. de Bono,Paul Workman,Anguraj Sadanandam,Matteo Fassan,Owen J. Sansom,Suzanne A. Eccles,Naureen Starling,Chiara Braconi,Chiara Braconi,Andrea Sottoriva,Simon P. Robinson,David Cunningham,Nicola Valeri,Nicola Valeri +49 more
TL;DR: Responses to anticancer agents ex vivo in organoids and PDO-based orthotopic mouse tumor xenograft models with the responses of the patients in clinical trials are compared to suggest that PDOs can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs.
Journal ArticleDOI
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Elizabeth C Smyth,Marcel Verheij,William H. Allum,David Cunningham,Andrés Cervantes,Dirk Arnold +5 more
Journal ArticleDOI
Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial
Elizabeth C Smyth,Andrew Wotherspoon,Clare Peckitt,David Gonzalez,Sanna Hulkki-Wilson,Zakaria Eltahir,Matteo Fassan,Massimo Rugge,Nicola Valeri,Nicola Valeri,Alicia Okines,Madeleine Hewish,William H. Allum,S. P. Stenning,Matthew Nankivell,Ruth E Langley,David Cunningham +16 more
TL;DR: In the MAGIC trial, MMRD and high MSI were associated with a positive prognostic effect in patients treated with surgery alone and a differentially negative prognosticEffect in patients treating with chemotherapy.
Journal ArticleDOI
Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer.
Filippo Pietrantonio,Rosalba Miceli,Alessandra Raimondi,Young-Woo Kim,Won Ki Kang,Ruth E Langley,Yoon Young Choi,Kyoung-Mee Kim,Matthew Nankivell,Federica Morano,Andrew Wotherspoon,Nicola Valeri,Nicola Valeri,Myeong Cherl Kook,Ji Yeong An,Heike I. Grabsch,Heike I. Grabsch,Giovanni Fucà,Sung Hoon Noh,Tae Sung Sohn,Sung Kim,Maria Di Bartolomeo,David Cunningham,Jeeyun Lee,Jae Ho Cheong,Elizabeth C Smyth +25 more
TL;DR: In patients with resectable primary GC, MSI is a robust prognostic marker that should be adopted as a stratification factor by clinical trials and Chemotherapy omission and/or immune checkpoint blockade should be investigated prospectively in MSI-high GCs according to clinically and pathologically defined risk of relapse.
Journal ArticleDOI
Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2–3 trial
David Cunningham,S. P. Stenning,Elizabeth C Smyth,Alicia Okines,William H. Allum,S Rowley,L. Stevenson,Heike I. Grabsch,Heike I. Grabsch,D Alderson,Thomas Crosby,S. Michael Griffin,Wasat Mansoor,Fareeda Y. Coxon,Stephen Falk,Suzanne Darby,K Sumpter,Jane M Blazeby,Ruth E Langley +18 more
TL;DR: The primary outcome for the phase 3 stage of the trial was overall survival (defined as the time from randomisation until death from any cause), analysed in the intention-to-treat population.